AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value, with the stock price up by 2.14% to the previous day’s close as strong demand from buyers drove the stock to $2.39.
Actively observing the price movement in the last trading, the stock closed the session at $2.34. Referring to stock’s 52-week performance, its high was $5.12, and the low was $2.20. On the whole, ABCL has fluctuated by -22.40% over the past month.
With the market capitalization of AbCellera Biologics Inc currently standing at about $712.19 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 26.29M, with a low estimate of 4.6M and a high estimate of 17M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 7.12M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABCL’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ABCL currently trading nearly -19.86% and -21.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 32.71, while the 7-day volatility ratio is showing 10.02% which for the 30-day chart, stands at 7.44%. Furthermore, AbCellera Biologics Inc (ABCL)’s beta value is 0.47, and its average true range (ATR) is 0.23.
A comparison of AbCellera Biologics Inc (ABCL) with its peers suggests the former has fared considerably weaker in the market. ABCL showed an intraday change of 2.14% in last session, and over the past year, it shrunk by -52.67%%. In comparison, AbbVie Inc. (ABBV) has moved higher at 1.82%% on the day and was up 16.83% over the past 12 months. On the other hand, the price of Genmab A/S ADR (GMAB) has risen 3.30%% on the day. The stock, however, is off -16.49% from where it was a year ago. Additionally, there is a gain of 1.97%% for Charles River Laboratories International Inc. (CRL) in last trading while the stock has seen an overall depriciation of -36.40%% over the past year.
Data on historical trading for AbCellera Biologics Inc (NASDAQ:ABCL) indicates that the trading volumes over the past 3 months, they’ve averaged 3.77 million. According to company’s latest data on outstanding shares, there are 295.16 million shares outstanding.
Nearly 24.86% of AbCellera Biologics Inc’s shares belong to company insiders and institutional investors own 37.06% of the company’s shares. The stock has fallen by -18.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABCL stock heading into the next quarter.
